TXMD
TherapeuticsMD Inc. · NASDAQ
- Market cap
- $21.6M
TherapeuticsMD Inc. (TXMD) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for TXMD, including 2 SEC filings and 1 earnings update. The most recent was published Nov 13, 2026.
Financial highlights
Full financials- Revenue, TTM
- $3.75M
- Revenue growth
- +33.9%
- Net income, TTM
- $122.0K
- Net margin
- 3.3%
- Cash
- $10.45M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks6+100%
2026-05-242026-11-15
Mix390d
- SEC Filings2(67%)
- Earnings1(33%)
Activity · 52 weeks167 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by TherapeuticsMD Inc.10-Q - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECTherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- PRTherapeuticsMD Announces Third Quarter 2026 Financial ResultsTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2026. Third Quarter 2026 Financial Results Net Income from Continuing Operations Net income from continuing operations totaled $501 thousand, or $0.04 per basic and diluted common share, compared to income from continuing operations of $50 thousand, or $0.00 per basic and diluted common share for the third quarter of 2025. License Revenues from Continuing Operations The Company recorded $1.3 million in license revenue for the third quarter of 2026, an increase of $475 thousand, o
- SECSEC Form 10-Q filed by TherapeuticsMD Inc.10-Q - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECTherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- PRTherapeuticsMD Announces Second Quarter 2026 Financial ResultsTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026. Second Quarter 2026 Financial Results Net Income from Continuing Operations Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025. License Revenues from Continuing Operations The Company recorded $864 thousand in license revenue, primarily from the Mayne License Agreement, for the second quarter of 2026, a decrease of $83 thousand, compared to $952 thousand in license revenue for the second quarter of
- SECSEC Form 10-Q filed by TherapeuticsMD Inc.10-Q - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECTherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- PRTherapeuticsMD Announces First Quarter 2026 Financial ResultsTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations totaled $103 thousand, compared to a net loss of $636 thousand for the first quarter of 2025. License Revenues from Continuing Operations The Company recorded $724 thousand in license revenue, primarily from the Mayne License Agreement, an increase of $331 thousand, compared to $393 thousand in license revenue for the first quarter of 2025. The increase is att
- SECAmendment: SEC Form 10-K/A filed by TherapeuticsMD Inc.10-K/A - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECSEC Form NT 10-K filed by TherapeuticsMD Inc.NT 10-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECTherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECSEC Form 10-K filed by TherapeuticsMD Inc.10-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- PRTherapeuticsMD Announces Full Year 2025 Financial ResultsTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(0.7) million, or $(0.06) per basic and diluted common share, an improvement of $1.7 million, compared to net loss from continuing operations of $(2.3) million, or $(0.20) per basic and diluted common share, for 2024. License Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $3.0 million during the year ended Decemb
- INSIDERDirector Thompson Tommy G bought $14,031 worth of shares (8,400 units at $1.67), increasing direct ownership by 57% to 23,179 units (SEC Form 4)4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
- SECTherapeuticsMD Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECTherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECSEC Form 10-Q filed by TherapeuticsMD Inc.10-Q - TherapeuticsMD, Inc. (0000025743) (Filer)
- PRTherapeuticsMD Announces Third Quarter 2025 Financial ResultsTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted common share, for the third quarter of 2024. License Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $784 thousand for the third quarter of 2025, an increase of $237
- INSIDERSEC Form 4 filed by Director Thompson Tommy G4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
- INSIDERSEC Form 4 filed by Director Naughton Gail K4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
- INSIDERSEC Form 4 filed by Director Collins Cooper C.4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Walker Marlan D4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
- SECSEC Form DEFA14A filed by TherapeuticsMD Inc.DEFA14A - TherapeuticsMD, Inc. (0000025743) (Filer)
- SECSEC Form DEF 14A filed by TherapeuticsMD Inc.DEF 14A - TherapeuticsMD, Inc. (0000025743) (Filer)
TXMD FAQ
10 questionsWhat does TherapeuticsMD Inc. do?
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product...What is the latest news on TXMD?
In the last 30 days Quantisnow tracked 3 wire items for TXMD: 2 SEC filings and 1 earnings update. The most recent was published on November 13, 2026.What is TXMD revenue?
TherapeuticsMD Inc. (TXMD) reported $3.75M of revenue for the twelve months ended Sep 30, 2026. That is up 33.9% from the year before. Revenue for fiscal 2025 was $3.02M.Is TXMD profitable?
Yes. TherapeuticsMD Inc. earned $122.0K in net income for the twelve months ended Sep 30, 2026, a net margin of 3.3%.How much cash and debt does TXMD have?
TherapeuticsMD Inc. reported $10.45M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does TXMD stock trade?
TherapeuticsMD Inc. (TXMD) is listed on NASDAQ.What sector and industry is TXMD in?
TherapeuticsMD Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TXMD?
TherapeuticsMD Inc. has had 2 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $2.50 price target on 2022-03-11. Recent price targets range from $2.50 to $3.00.What companies are similar to TXMD?
Notable peers in the same industry include OGN (Organon & Co.), PFE (Pfizer Inc.), AMRX (Amneal Pharmaceuticals Inc.), VTRS (Viatris Inc.). Compare TXMD side-by-side with any of them on Quantisnow.How can I track TXMD on Quantisnow?
Quantisnow aggregates TherapeuticsMD Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TXMD to receive live email and push alerts on every new disclosure.